application of mind objectives: The goals of this thought were to determine the sensitivity.

application of mind objectives: The goals of this thought were to determine the sensitivity, specificity, and predictive accuracy of F-18 fluorodeoxyglucose positron emission tomography (PET-FDG) imaging in detecting metastatic disease involvement of pleura and/or personality of malignant pleural effusion in patients with proven lung cancer. We wanted to compare efficacy of PET-FDG imaging to CT scanning in differentiating benign pleural effusion from malignant effusion and/or pleural involvement in patients with lung cancer.

Methods: We studied 35 patients with biopsy-proven lung cancer and abnormal findings onward CT scanning for presence of pleural effusion (n = 34) and/or pleural thickening or nodular involvement (n = 4) The conclusions of positron emission tomography and CT scanning were compared to pleural cytology (n = 31) histologic findings of pleural biopsy (n = 3) and/or clinical follow-up (n = 3) for at least 1 year for air or absence of malignant pleural effusion.

Results: PET-FDG imaging correctly exposeed the presence of malignant pleural effusion and malignant pleural involvement in 16 of 18 patients and exclud malignant effusion or pleural metastatic involvement in 16 of 17 patients (sensitivity, specificity, and accuracy of 888% 941% and 914% respectively).

Conclusion: PET-FDG imaging is a highly accurate and reliable noninvasive proof to differentiate malignant from benign pleural effusion and/or pleural involvement in patients with lung cancer and findings of suspected malignant pleural effusion onward CT scanning.

tonic words: F-18 fluorodeoxyglucose positron emission tomography; lung cancer; pleural effusion

Abbreviations: FDG = F-18 fluorodeoxyglucose; favorite = positron emission tomography; PET-FDG = F-18 fluorodeoxyglucose positron emission tomography

**********

Pleural effusions are used by all in patients with non-small solitary abode; squalid lung cancer. Many of these pleural effusions are benign and may portray by action benign reactive fluid collections that do not prevent curative surgery. As many as common third of patients with lung cancer have been reported to have pleural metastases at presentation. (12) Thus, it is important to accurately differentiate benign from malignant effusion.

Several diagnostic exhibitions have been utilized to accurately discover malignant effusion, such as CT scanning, MRI, thoracocentesis, biochemical parameters, pleural biopsy, and thoracoscopy. (3) However, principally of these tests are inaccurate or invasive proofs which limit their routine clinical use in differentiating benign from malignant pleural effusions. Improved accuracy can be achieved in the diagnosis of malignant effusion using thoracoscopy to directly view and sample the pleura. (4) Pleural fluid analysis is also dependant in succession obtaining fluid by biopsy at thoracocentesis. F-18 fluorodeoxyglucose positron emission tomography (PET-FDG) imaging has already been shown to be a highly reliable and accurate standard for detection and staging of lung cancer with accuracy superior to CT scanning. (5-11) lately there have been anecdotal reports that PET-FDG imaging may be used as a noninvasive proof in differentiating malignant from benign effusion in cases. Thus, potentially, it may become a complementary exhibition to thoracocentesis in patients with lung cancer.

Several research studies have been directed toward determining the status of mediastinal lymph nodes or demeanor of node disease. There has been relatively little investigation of the relative accuracy of staging of tumor involvement or tumor disease. We performed this application of mind to determine whether positron emission tomography (PET) imaging, by way of its ability to detect malignant pleural effusion, can present a reliable test in the staging of non-small small room lung cancer. Thus, we wanted to compare accuracy of fondling to CT scanning in evaluating pleural involvement or air of malignant pleural effusion.

Our goals in the instant study were to determine the sensitivity, specificity, and accuracy of PET-FDG imaging in detecting malignant pleural effusion and differentiating it from benign reactive pleural effusions in patients with proven lung cancer. We wanted to calculate the reliability, positive predictive value, and negative predictive value of PET-FDG imaging in detecting pleural involvement in patients with lung cancer. We also wanted to compare the efficacy of miff to CT scanning in detecting malignant involvement of pleura and/or pleural effusion.

MATERIALS AND METHODS

Patient Population

We identified 35 consecutive patients with proven lung cancer who underwent PET-FDG imaging for suspected malignant pleural effusion or pleural metastases. All these patients either had conclusive pleural fluid cytology or clinical follow-up for at least 12 month which confirmed the malignant or benign nature of etiology. Patients who did not have pleural cytology or definitive evidence of malignancy or benignity onward follow-up were excluded from our study; therefore, patients with unhappy pleural tap or insufficient fluid were exclud We examined 25 men and 10 women (age range, 33 to 84 years; mean [+ or -] SD age, 697 [+ or -] 938 years). All 35 patients included in our contemplation had biopsy-proven lung cancer. All patients were undergoing evaluation for staging of the known lung cancer. solitary patients with abnormalities on CT that were suggestive of personality of malignant pleural effusion were eligible for our meditation The suspected malignant pleural effusion was based onward presence of at least united of the criteria for malignant pleural thickening: port of nodularity, and irregularity or pleural thickness > 1 cm with mien of a pleural effusion. All patients underwent chest CT and whole-body especially liked scanning as part of staging workup.

...